BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

...companies. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) has a MAT2A inhibitor in Phase I testing, Repare and Artios Pharma Ltd....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...with a $115.5 million series A round (see “A Passage to Optimal CNS Vectors” ). Artios Pharma Ltd....
...of research at the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. CureDuchenne Neurogene Inc. Artios Pharma Ltd. HemoShear...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Small molecules Cardiovascular Mission Therapeutics Ltd. $118.0 2/2/16 Deubiquitylating (DUB) enzyme inhibitors Endocrine/ metabolic, neurology Artios Pharma Ltd....
...Partners, Novo Seeds, Merck KGaA, Sunstone Capital Small molecule galectin modulators Pulmonary, hepatic, opthalmic, cancer Artios Pharma Ltd....
BioCentury | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

...first CBO. She was CBO at Portal Instruments Inc. (Cambridge, Mass.). DNA damage response play Artios Pharma Ltd....
...and manages a portfolio of development partnerships aimed at neglected diseases. BioCentury Staff AACR Acadia Pharmaceuticals Inc. Aerie Pharmaceuticals Inc. Artios Pharma Ltd. Audentes...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...is succeed by Pierre Legault, who also serves as chairman of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd....
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s $70M Series B” & “Artios...
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

...With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA...
...could improve upon PARP inhibitors -- and the funds to take them to the clinic. Artios...
...repair pathway within which PARP works. SV Health Investors helped turn a CRUK program into Artios...
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...CEO. He succeeds acting CEO Robin Quirk, who will become COO. Staples was CBO at Artios Pharma Ltd....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...with the larger rounds going to biotechs with platform technologies like Crescendo Biologics Ltd. or Artios Pharma Ltd....
...NASDAQ:AMRN), Dublin, Ireland Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Pasadena, Calif. Artios Pharma Ltd....
BioCentury | Oct 5, 2018
Finance

Fruitful partnerships

...Harpoon Therapeutics Inc., directed viral nanoparticle company Aura Biosciences Inc. and DNA damage response company Artios Pharma Ltd....
Items per page:
1 - 10 of 24
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

...companies. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) has a MAT2A inhibitor in Phase I testing, Repare and Artios Pharma Ltd....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...with a $115.5 million series A round (see “A Passage to Optimal CNS Vectors” ). Artios Pharma Ltd....
...of research at the Muscular Dystrophy Association. BioCentury Staff Passage Bio Inc. Novartis AG Hisamitsu Pharmaceutical Co. Inc. Illumina Inc. CureDuchenne Neurogene Inc. Artios Pharma Ltd. HemoShear...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Small molecules Cardiovascular Mission Therapeutics Ltd. $118.0 2/2/16 Deubiquitylating (DUB) enzyme inhibitors Endocrine/ metabolic, neurology Artios Pharma Ltd....
...Partners, Novo Seeds, Merck KGaA, Sunstone Capital Small molecule galectin modulators Pulmonary, hepatic, opthalmic, cancer Artios Pharma Ltd....
BioCentury | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

...first CBO. She was CBO at Portal Instruments Inc. (Cambridge, Mass.). DNA damage response play Artios Pharma Ltd....
...and manages a portfolio of development partnerships aimed at neglected diseases. BioCentury Staff AACR Acadia Pharmaceuticals Inc. Aerie Pharmaceuticals Inc. Artios Pharma Ltd. Audentes...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...is succeed by Pierre Legault, who also serves as chairman of Poxel S.A. (Euronext:POXEL) and Artios Pharma Ltd....
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...million ($84.3 million) series B for Artios Pharma Ltd. (see “Andera Leads Crescendo’s $70M Series B” & “Artios...
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

...With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA...
...could improve upon PARP inhibitors -- and the funds to take them to the clinic. Artios...
...repair pathway within which PARP works. SV Health Investors helped turn a CRUK program into Artios...
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...CEO. He succeeds acting CEO Robin Quirk, who will become COO. Staples was CBO at Artios Pharma Ltd....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...with the larger rounds going to biotechs with platform technologies like Crescendo Biologics Ltd. or Artios Pharma Ltd....
...NASDAQ:AMRN), Dublin, Ireland Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Pasadena, Calif. Artios Pharma Ltd....
BioCentury | Oct 5, 2018
Finance

Fruitful partnerships

...Harpoon Therapeutics Inc., directed viral nanoparticle company Aura Biosciences Inc. and DNA damage response company Artios Pharma Ltd....
Items per page:
1 - 10 of 24